Cancer Consultants Cancer News for Professionals

High-dose Mixed Proton and Photon Radiotherapy May Improve Treatment of Prostate Cancer

jmaxon@onco-ed.com (jenny maxon) — Fri, 13 Nov 2009 14:16:51 GMT

Researchers affiliated with the Proton Radiation Oncology Group (PROG)/American College of Radiology (ACR) 95-09 study have reported that mixed proton and photon radiotherapy improves outcomes of patients with low- and intermediate-risk prostate cancer. The details of this randomized trial were presented at the 2009 meeting of the American Society of Radiation Therapy and Oncology (ASTRO) in the first week of November.

Early Morning Colonoscopies Detect More Polyps

jmaxon@onco-ed.com (jenny maxon) — Fri, 13 Nov 2009 14:04:33 GMT

Researchers affiliated with the Veterans Administration of greater Los Angeles have reported that a greater number of polyps was detected among patients seen early in the morning than among patients seen later in the day. The reasons for this are uncertain, but it’s possible that the lower rate of polyp detection later in the day is the result of provider fatigue or less complete bowel preparation. These results were published in November, 2009 issue of Clinical Gastroenterology and Hepatology.

Primary Care Physicians May Be Ordering More Pap Smears Than Necessary

jmaxon@onco-ed.com (jenny maxon) — Fri, 13 Nov 2009 13:58:21 GMT

Researchers from the National Institutes of Health have reported that primary care physicians overuse Pap smear testing and are not following current recommendations. The details of this study appeared in the November 3, 2009 issue of the Annals of Internal Medicine.

Excess Body Weight Linked with More Than 100,000 New Cancer Diagnoses Each Year in U.S.

jmaxon@onco-ed.com (jenny maxon) — Thu, 12 Nov 2009 12:23:12 GMT

According to estimates from the American Institute for Cancer Research (AICR), excess body weight may be responsible for more than 100,000 new cancer diagnoses each year in the United States.

Israeli Jewish Holocaust Survivors May Have Increased Risk of Cancer

jmaxon@onco-ed.com (jenny maxon) — Thu, 12 Nov 2009 12:13:04 GMT

Researchers from Israel have reported that the incidence of all cancers, and especially breast and colorectal cancers, is higher among Israeli Jews who were potentially exposed to the Holocaust compared with those who were not. The details of this study were published in the November 4, 2009 issue of the Journal of the National Cancer Institute.

Adjuvant Radiotherapy Improves Local Control in High-risk Melanoma Patients

jmaxon@onco-ed.com (jenny maxon) — Thu, 12 Nov 2009 12:04:21 GMT

Researchers affiliated with the Intergroup Randomized Trial (TROG 01.01/ANZMTG 01.02) have reported that adjuvant radiotherapy (RT) improves regional control for patients with high-risk melanoma without a statistically significant effect on survival. The details of this study were presented at the 2009 meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO).

Carbogen and Nicotinamide Improves Survival of Patients with Advanced Bladder Cancer Receiving Radiotherapy

jmaxon@onco-ed.com (jenny maxon) — Wed, 11 Nov 2009 16:16:56 GMT

Researchers from the UK have reported that patients with locally advanced bladder cancer treated with concomitant carbogen, nicotinamide, and radical accelerated radiotherapy have a 13% improved three-year survival compared with patients treated with radiotherapy alone. The details of this Phase III randomized trial were presented at the 2009 meeting of the American Society of Therapeutic Radiology and Oncology (ASTRO) in the first week of November.

H-R3 (Nimotuzumab) Enhances Radiation and Chemotherapy Responses in Advanced Head and Neck Cancer

jmaxon@onco-ed.com (jenny maxon) — Wed, 11 Nov 2009 16:08:20 GMT

Researchers from India have reported that the addition of nimotuzumab to radiation therapy or radiation therapy plus chemotherapy increases long-term loco-regional control and survival in patients with advanced head and neck cancer. The details of this Phase IIB study were presented at the 2009 meeting of the American Society for Therapeutic Radiation and Oncology (ASTRO).

Adjuvant Erbitux® May Improve Survival of High-risk Resected Head and Neck Cancer

jmaxon@onco-ed.com (jenny maxon) — Wed, 11 Nov 2009 15:55:39 GMT

Researchers affiliated with RTOG 0234 have reported that the addition of Erbitux® (cetuximab) may improve outcomes of patients with high-risk resected head and neck cancer receiving chemoradiotherapy. The details of this study were presented at the 2009 meeting of the American Society for Therapeutic Radiology and Oncology in the first week of November.

Radiotherapy and Hormonal Therapy Effective for Men with Prostate Cancer Failing Surgery

jmaxon@onco-ed.com (jenny maxon) — Tue, 10 Nov 2009 11:16:48 GMT

Researchers from the Mayo Clinic have reported that relapse-free survival was over 90% in patients treated with salvage radiotherapy (RT) plus two years of androgen deprivation therapy (ADT) for post-prostatectomy relapse. The details of this study were presented at the 2009 meeting of the American Society of Therapeutic Radiology and Oncology in the first week in November, 2009.